Skip to main content

NCT03832569 - Study of Pembrolizumab or Placebo Following Surgery in Patients With Microsatellite Instability High (MSI-H) Solid Tumors

Brief Title
Study of Pembrolizumab or Placebo Following Surgery in Patients With Microsatellite Instability High (MSI-H) Solid Tumors
Protocol ID
NCT03832569
Brief Summary
Conditions:   Solid Tumors;   Identified by NGS, PCR or IHC
Interventions:   Drug: Pembrolizumab;   Drug: Placebo
Sponsors:   Memorial Sloan Kettering Cancer Center;   Merck Sharp & Dohme Corp.
Recruiting
Pub Date: 
Wednesday, February 6, 2019 - 10:00am
Study URL: 
https://clinicaltrials.gov/ct2/show/NCT03832569?term=genomics%20DNA&%3Brecrs=abc